SCHEMBL29699229

SCHEMBL29699229

Nc1ncc2cc(Br)ccc2n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 2/20 0.55
PABPC1 P11940 1/20 0.53
LCK P06239 2/20 0.49
KDR P35968 1/20 0.49
JAK3 P52333 1/20 0.49
MAPK14 Q16539 1/20 0.49
CLK1 P49759 3/20 0.47
CSNK1D P48730 1/20 0.47
CSNK1E P49674 1/20 0.47
DYRK1A Q13627 1/20 0.47
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 1/20 0.42
MAPT P10636 1/20 0.42
KMT2A Q03164 1/20 0.42
HTT P42858 1/20 0.41
ROCK1 Q13464 1/20 0.41
ADORA2A P29274 1/20 0.40
CDK5 Q00535 2/20 0.39
CDK5R1 Q15078 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL46742 1.00 BACE1 (0.55) BACE1PABPC1LCKKDRJAK3
SCHEMBL5132808 0.84 KDR (0.48) BACE1PABPC1LCKKDRJAK3
SCHEMBL1741867 0.84 BACE1 (0.57) BACE1PABPC1KDRCLK1CSNK1D
SCHEMBL30380023 0.84 BACE1 (0.57) BACE1PABPC1KDRCLK1CSNK1D
SCHEMBL1461279 0.79 BACE1 (0.48) BACE1PABPC1DYRK1AKDM4EMEN1
SCHEMBL30839232 0.79 BACE1 (0.48) BACE1PABPC1DYRK1AKDM4EMEN1
SCHEMBL30912753 0.79 EGFR (0.57) LCKKDRJAK3MAPK14CLK1
SCHEMBL610225 0.79 EGFR (0.57) LCKKDRJAK3MAPK14CLK1
SCHEMBL1570979 0.76 BACE1 (0.46) BACE1PABPC1MEN1KMT2AHTT
SCHEMBL15679285 0.76 LCK (0.49) LCKKDRJAK3MAPK14CLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365546-A1 5-SUBSTITUTED INDOLE 3-AMIDE DERIVATIVES, PREPARATION METHOD AND USE THEREOF ORIGIANT PHARMACEUTICAL CO., LTD (CN) 2023-11-16 US disclosed
EP-4247795-A1 GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF Deciphera Pharmaceuticals, LLC (US) 2023-09-27 EP disclosed
EP-4212525-A1 5-SUBSTITUTED INDOLE 3-AMIDE DERIVATIVE, PREPARATION METHOD AND USE THEREOF Origiant Pharmaceutical Co., Ltd (CN) 2023-07-19 EP disclosed
WO-2022109001-A1 GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC (US) 2022-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365546-A1 5-SUBSTITUTED INDOLE 3-AMIDE DERIVATIVES, PREPARATION METHOD AND USE THEREOF RIPK1, RIPK3, RIPK2 BACE1 1832/4885PABPC1 3148/4885LCK 1017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.